On March 1, 2022, Sandoz Canada completed the sale of its Boucherville, Quebec, manufacturing plant to Delpharm. The transaction involved the largest sterile injectable production facility in Canada, which supplies critical medicines to Canadian and US healthcare systems. Despite the sale, Sandoz Canada retained ownership of marketing authorizations and intellectual property, maintaining commercial responsibility for its products. Delpharm plans to invest in the site and explore business development opportunities to support growth.

Michel Robidoux, President and General Manager of Sandoz Canada, highlighted the partnership's reliability, emphasizing a long-term agreement ensuring continuous supply of medicines and job retention at the Boucherville facility. The transaction was facilitated by legal advisors Miller Thomson and Freshfields Bruckhaus Deringer for Sandoz Canada and Gowling WLG for Delpharm. Delpharm aims to uphold the high-quality formulations of Sandoz Canada's injectable products, manufactured by the same expert team, ensuring consistent support for patients, hospitals, physicians, and pharmacists with a wide range of biosimilar and generic medicines.